Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Sex ratio of multiple sclerosis in Canada: a longitudinal study.
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Current and future drugs for treatment of MS-associated bladder dysfunction.
The King-Devick (K-D) test of rapid eye movements: A bedside correlate of disability and quality of life in MS.
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
HLA-A(∗)02, gender and tobacco smoking, but not multiple sclerosis, affects the IgG antibody response against human herpesvirus 6.
European medicines agency's committee for medicinal products for human use issues positive opinion on marketing authorisation application for Fampyra
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
Novartis updates US label on Gilenya® following discussions with the FDA
Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System.
Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis.
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study.
Liver X receptors alpha and beta promote myelination and remyelination in the cerebellum.
Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.
What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature.
Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases.
Rush University Medical Center Sells AMPYRA® Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Genetic burden of common variants in progressive and bout-onset multiple sclerosis.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
The "liberation procedure" for multiple sclerosis: sacrificing science at the altar of consumer demand.
Quantitative MRI and Cerebrospinal Fluid Inflammatory Mediators in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis before and after Treatment with Immunomodulators: A Longitudinal Study.

Pages